Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics
Alvotech’s Merger with Oaktree Acquisition Corp. II
Cooley and Arendt advised Alvotech Holdings, while Kirkland & Ellis, working alongside Walkers and King & Spalding and Elvinger Hoss Prussen, advised Oaktree Acquisition Corp. II...
Boston Scientific’s $1.75 Billion Acquisition of Baylis Medical Company
Shearman & Sterling advised Boston Scientific Corporation on the acquisition of Baylis Medical Company, assisted by BCF Business Law, in collaboration with Cooley LLP (U.S. lead...
ZOLL Medical’s $538 Million Acquisition of Itamar Medical
Latham & Watkins and Goldfarb Seligman & Co. represented Itamar Medical in the transaction. Cooley and Gornitzky & Co. advised ZOLL Medical. Itamar™ Medical Ltd. (Nasdaq...
Lyell Immunopharma’s $425 Million Initial Pubic Offering
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...